REGULAR CONTENT
Final ID
539
Type
Original Scientific Research-Oral or Pos
Authors
A Graif1, R Patel2, G McKenna1, C Fedele1, A Vance1, K Lie1, S Putnam1, D Leung1, C Grilli1
Institutions
1Christiana Care Health System, Newark, DE, 2Sidney Kimmel Medical College, Philadelphia, PA
Purpose
To evaluate the necessity of prophylactic post-procedural administration of antibiotics (ABX) after uterine fibroid embolization (UFE) in the prevention of procedure-related infections.
Materials & Methods
Patients undergoing UFE at a single center between June 2015 and August 2016 were enrolled in a prospective cohort study and divided into 2 groups. The control group consisted of patients treated before January 2016, who were prescribed post-procedural oral Ciprofloxacin 500mg BID for 7 days. The study group consisted of patients treated after January 2016, who were not prescribed post-procedural ABX. A single dose of pre-procedural ABX was administered to all patients per SIR guidelines. Patient demographics, procedure details and 30-day follow-up data were collected. The primary endpoint of the study was infection rate within 30 days of the procedure.
Results
A total of 85 patients were enrolled in the study, consisting of 48 in the control group and 37 in the study group. Patient demographics and procedure details were similar in both groups. Apart from 6 patients in the study group who underwent UFE with Embozene particles (Boston Scientific, Marlborough, MA), all patients underwent UFE utilizing Embosphere particles (Merit Medical Systems, South Jordan, UT). A single patient in the study group presented with malodorous discharge 15 days postop and was treated with oral ABX. No infectious complications were recorded in the control group. The difference in infection rate between the groups was not statistically significant (p=0.435).
Conclusions
Withholding prophylactic post-procedural ABX did not result in a significantly increased rate of procedure-related infections. However, the study is under-powered to demonstrate non-inferiority of the study group, as the reported post-UFE infection rate is exceedingly low. Nonetheless, this pilot study does serve as a model for a larger scale study.
Final ID
539
Type
Original Scientific Research-Oral or Pos
Authors
A Graif1, R Patel2, G McKenna1, C Fedele1, A Vance1, K Lie1, S Putnam1, D Leung1, C Grilli1
Institutions
1Christiana Care Health System, Newark, DE, 2Sidney Kimmel Medical College, Philadelphia, PA
Purpose
To evaluate the necessity of prophylactic post-procedural administration of antibiotics (ABX) after uterine fibroid embolization (UFE) in the prevention of procedure-related infections.
Materials & Methods
Patients undergoing UFE at a single center between June 2015 and August 2016 were enrolled in a prospective cohort study and divided into 2 groups. The control group consisted of patients treated before January 2016, who were prescribed post-procedural oral Ciprofloxacin 500mg BID for 7 days. The study group consisted of patients treated after January 2016, who were not prescribed post-procedural ABX. A single dose of pre-procedural ABX was administered to all patients per SIR guidelines. Patient demographics, procedure details and 30-day follow-up data were collected. The primary endpoint of the study was infection rate within 30 days of the procedure.
Results
A total of 85 patients were enrolled in the study, consisting of 48 in the control group and 37 in the study group. Patient demographics and procedure details were similar in both groups. Apart from 6 patients in the study group who underwent UFE with Embozene particles (Boston Scientific, Marlborough, MA), all patients underwent UFE utilizing Embosphere particles (Merit Medical Systems, South Jordan, UT). A single patient in the study group presented with malodorous discharge 15 days postop and was treated with oral ABX. No infectious complications were recorded in the control group. The difference in infection rate between the groups was not statistically significant (p=0.435).
Conclusions
Withholding prophylactic post-procedural ABX did not result in a significantly increased rate of procedure-related infections. However, the study is under-powered to demonstrate non-inferiority of the study group, as the reported post-UFE infection rate is exceedingly low. Nonetheless, this pilot study does serve as a model for a larger scale study.